Literature DB >> 8132698

7-Hydroxycoumarin inhibits oncogene-induced transformation of murine fibroblasts.

B Seliger1, H Pettersson.   

Abstract

7-Hydroxycoumarin (7-HC) is a naturally occurring substance with a variety of biological activities, e.g. antitumoral and immunomodulatory action. The potential mechanisms of 7-HC action on tumor cells have been investigated in a model of mouse fibroblasts transformed by distinct retroviral vectors carrying the oncogenes myc and ras. Treatment of the different oncogenic transformants with 7-HC in non-cytotoxic concentrations causes a strong inhibition of their proliferative capacity as measured by growth curves. Furthermore, incubation of the ras and myc transformants with 7-HC abrogated soft agar colony formation when compared to untreated cultures. These changes in cell growth characteristics of the various oncogene-transformed mouse fibroblasts were transient, since removal of 7-HC from the cultures caused a reappearance of the transformed properties of these cells within 6 days. The 7-HC-mediated inhibition of the proliferative capacity of the transformants was preceded by a selective down-regulation of oncogene expression. These data suggest that 7-HC causes a reversible inhibition of ras- and myc-induced neoplastic properties in transformed fibroblasts by selective down-regulation of retroviral RNA levels.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8132698     DOI: 10.1007/bf01377119

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  14 in total

Review 1.  The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds.

Authors:  D Egan; R O'Kennedy; E Moran; D Cox; E Prosser; R D Thornes
Journal:  Drug Metab Rev       Date:  1990       Impact factor: 4.518

Review 2.  Regulation of cell proliferation and differentiation by interferons.

Authors:  M J Clemens; M A McNurlan
Journal:  Biochem J       Date:  1985-03-01       Impact factor: 3.857

3.  Cimetidine and coumarin therapy of melanoma.

Authors:  R D Thornes; G Lynch; M V Sheehan
Journal:  Lancet       Date:  1982-08-07       Impact factor: 79.321

4.  A new dominant hybrid selective marker for higher eukaryotic cells.

Authors:  F Colbère-Garapin; F Horodniceanu; P Kourilsky; A C Garapin
Journal:  J Mol Biol       Date:  1981-07-25       Impact factor: 5.469

5.  The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes.

Authors:  R W Ellis; D Defeo; T Y Shih; M A Gonda; H A Young; N Tsuchida; D R Lowy; E M Scolnick
Journal:  Nature       Date:  1981-08-06       Impact factor: 49.962

6.  Murine gamma interferon inhibits v-mos-induced fibroblast transformation via down regulation of retroviral gene expression.

Authors:  B Seliger; G Kruppa; K Pfizenmaier
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

7.  Prevention of tumorigenesis of oncogene-transformed rat fibroblasts with DNA site inhibitors of poly(ADP ribose) polymerase.

Authors:  A Tseng; W M Lee; E B Jakobovits; E Kirsten; A Hakam; J McLick; K Buki; E Kun
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

8.  Coumarin (1,2-benzopyrone) enhances DR and DQ antigen expressions by peripheral blood mononuclear cells in vitro.

Authors:  M E Marshall; J L Rhoades; C Mattingly; C D Jennings
Journal:  Mol Biother       Date:  1991-12

9.  Treatment of metastatic renal cell carcinoma with coumarin (1,2-benzopyrone) and cimetidine: a pilot study.

Authors:  M E Marshall; L Mendelsohn; K Butler; L Riley; J Cantrell; C Wiseman; R Taylor; J S Macdonald
Journal:  J Clin Oncol       Date:  1987-06       Impact factor: 44.544

10.  Gamma interferon regulates long terminal repeat-controlled oncogene expression in transformed mouse fibroblasts at the level of mRNA transcription.

Authors:  B Seliger; G Kruppa; R Schäfer; S M Redmond; K Pfizenmaier
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.